Across the Nutra-verse: Clorox’s financials, astaxanthin from Indonesia, and more

By Stephen Daniells

- Last updated on GMT

© Getty Images / denphumi
© Getty Images / denphumi
A lot has happened over the past seven days: Stay on top of the global nutra-news with our weekly round-up of key news from across the globe.


Clorox’s financials: Nutranext supplement continue to perform, but probiotics have problems

The Clorox Company reported that sales for its lifestyle segment, which includes brands associated with the 2018 acquisition of Nutranext, were flat for the quarter, but for the full year were up 17%.

“I continue to be pleased with the Nutranext acquisition, which delivered robust growth in the fourth quarter and contributed strongly to total company fiscal year sales behind an integration that remains on track,” ​said CEO Benno Dorer in an earlings call with analysts. 

However, probiotics did not perform as well. Clorox acquired probiotic brand ReNew Life for $290 million in 2016. At the time of the acquisition the company said ReNew Life had generated sales of $115 million in 2015.

The company reported that sales were down by double-digits for both Q4 and for the year.

For more on this, please click HERE​.


ChromaDex gets EU novel foods approval for nicotinamide riboside

California-based ChromaDex has received a positive opinion from the European Food Safety Authority (EFSA) for the safety of its nicotinamide riboside (NR) chloride ingredient (Tru Niagen) as a reliable niacin (vitamin B3) source.

EFSA stated that NR is safe at levels up to 300 milligrams per day (mg/day), for the healthy adult population, excluding pregnant and lactating women. For pregnant and lactating women, an intake of up to 230 mg/day was deemed safe.

“Safety is paramount for ChromaDex and this positive opinion from EFSA underscores our depth of science, and is the latest in a consistently positive series of reviews of NR by authoritative bodies,” ​said ChromaDex CEO Rob Fried.

For more on this, please click HERE​.


Indonesian algae player enters global astaxanthin market

Astaxanthin © Getty Images Hendra Su
Health benefits associated with the the pinkish-red pigment astaxanthin include cardiovascular, joint, and skin health, to name but a few. Image © Getty Images / Hendra Su

There’s a new player in the astaxanthin market with Indonesia’s first microalgae firm PT Evergen Resources, which was inaugurated late last month.

The company, which is located in Kendal, Central Java, will produce and sell its astaxathin from freshwater microalgae Haematococcus pluvialis​ under the brand AstaLuxe. The company is targeting the local nutraceutical, pharmaceutical, and cosmetics industry.

“Our short term goal is to produce high quality of natural astaxanthin and to fulfill domestic market and exported it to various countries which are currently dominated by suppliers from the United States, Israel, Japan and Iceland,”​ said Founder and CEO Siswanto Harjanto.

For more on this story from NutraIngredients-Asia, please click HERE​.

Related news

Show more